ストックスクリーナーアプリを入手
216.12
3.04%
6.38
アフターアワーズ：
216.12
Biogen Inc (BIIB) 最新ニュース
Biogen Says Research, Milestone Charges to Reduce Earnings in Q2, Q3 - marketscreener.com
Biogen (BIIB) Projects Significant Expenses for 2026 - GuruFocus
Biogen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Biogen (NASDAQ: BIIB) projects large 2026 R&D milestone charges hitting EPS - Stock Titan
The Spinraza therapyBiogen Inc. leans on long-term SMA demand - AD HOC NEWS
Amgen or Biogen: Which Biotech Stock Appears Better Poised? - TradingView
BIIBBiogen Inc Latest SEC Filings - Finviz
Biogen reports steady outlook, analysts weigh Alzheimer’s and neurology pipeline - AD HOC NEWS
Biogen Inc.(NasdaqGS: BIIB) dropped from Russell 1000 Value-Defensive Index - marketscreener.com
Biogen Inc.(NasdaqGS: BIIB) dropped from Russell 1000 Defensive Index - marketscreener.com
Biogen: Key Takeaways From Needham’s Meeting With Top Management - Benzinga
Biogen (BIIB) Moves 7.0% Higher: Will This Strength Last? - Yahoo Finance
Block & Leviton LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Biogen, Inc. – BIIB - GlobeNewswire Inc.
Biogen to present Alzheimer’s drug data at upcoming conference - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen - Biogen
Biogen to Highlight Breadth of Alzheimer’s Disease - GlobeNewswire
BIIB Maintained by Needham -- Price Target Raised to $256 - GuruFocus
The Vumerity from Biogen Inc.oral MS therapy with a quieter side-effect profile - AD HOC NEWS
Biogen Inc. stock outperforms competitors on strong trading day - MSN
Biogen (BIIB) Is Up 9.9% After US$1 Billion RayThera Deal And Salanersen WinHas The Bull Case Changed? - simplywall.st
Biogen shares at a four month high, analysts still watch BIIB - Ad-hoc-news.de
Biogen (BIIB) Research Report - StockStory
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Biogen clears a fresh 52-week high, shares react to RayThera deal and FDA tag - AD HOC NEWS
Enterprise value to revenue forward of Biogen Inc. – MUN:IDP - TradingView
Biogen (BIIB) Is Betting Its Next Phase Of Growth On Four New Drugs - simplywall.st
Biogen Inc (BIIB) Shares Surge 7.0% -- What GF Score of 74 Tells Investors - GuruFocus
Why Biogen (BIIB) Stock Is Up Today - Yahoo Finance
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout - Reuters
Biogen Jumps 6.1% Amid Sector-Wide Rally - AlphaStreet
Can Biogen's New Drugs Revive Growth Amid Legacy Sales Slump? - Yahoo Finance
Biogen reaches fresh 52-week high, shares extend strong S&P 500 run - Ad-hoc-news.de
Enterprise value to EBIT forward of Biogen Inc. – NASDAQ:BIIB - TradingView
Biogen Inc. stock underperforms Thursday when compared to competitors - MSN
Biogen Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Enterprise value to EBIT forward of Biogen Inc. – HAM:IDP - TradingView
Biogen marks a fresh 52-week high, shares extend NASDAQ biotech rally - Ad-hoc-news.de
Biogen stock reaches 52-week high at 206.21 USD By Investing.com - Investing.com South Africa
Biogen stock reaches 52-week high at 206.21 USD - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc.BIIB - PR Newswire
Price to sales forward of Biogen Inc. – NASDAQ:BIIB - TradingView
Biogen (BIIB) Could Be 9% Undervalued As Pipeline Hopes Shape The Valuation - simplywall.st
Enterprise value to EBITDA forward of Biogen Inc. – NASDAQ:BIIB - TradingView
Price to book forward of Biogen Inc. – TURQUOISE:BIIBN - TradingView
Enterprise value to revenue forward of Biogen Inc. – NASDAQ:BIIB - TradingView
Price to earnings forward of Biogen Inc. – NASDAQ:BIIB - TradingView
Biogen Expands Spinraza Patent Fight With Cipla, Somerset Suits - Bloomberg Law News
Biogen updates Alzheimer’s pipeline plans, shares on Nasdaq in focus - Ad-hoc-news.de
Law firm investigates Biogen for possible securities fraud after study misses key endpoint, stock drops 6.4%. - Pluang
Biogen to Acquire RayThera for Up to $1 Billion - Global Legal Chronicle
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Omada Health, Inc. (OMDA) - The Globe and Mail
WilmerHale Advises Biogen in Acquisition of RayThera - WilmerHale
Cantor Fitzgerald maintains Biogen stock rating on BIIB080 outlook - Investing.com
Biogen to acquire RayThera for USD 1B - Medical Buyer
Biogen Inc. (BIIB) Investor Outlook: Evaluating the Potential 12% Upside with Strong Buy Ratings - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Is Investigating Biogen Inc. (BIIB) And Encourages Shareholders to Connect - ACCESS Newswire
1.84%
大文字化:
|
ボリューム (24 時間):